FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W79968274> ?p ?o ?g. }

• W79968274 endingPage "3249" @default.
• W79968274 startingPage "3241" @default.
• W79968274 abstract "Abstract We designed a multicenter randomized trial comparing chemotherapy with daunorubicin-Ara C (chemotherapy group) and all transretinoic acid (ATRA) combined to the same chemotherapy (ATRA group) in newly diagnosed APL patients aged 65 years or less. The major endpoint of the study was event-free survival (EFS) (“events” being defined as failure to achieve complete remission [CR], occurrence of relapse, or death in CR). Early termination of the trial was decided after the first interim analysis, as EFS was significantly higher in the ATRA group. At the time, 101 patients had been randomized (54 in the ATRA group and 47 in the chemotherapy group). In the ATRA group, 49 (91%) patients achieved CR, 5 (9%) had early death, and 0 had resistant leukemia, compared with 38 (81%), 4 (8%), and 5 (10%) patients, respectively, in the chemotherapy group. The difference in CR rate between the two groups was not significant. The duration of coagulopathy was significantly reduced in the ATRA group, compared with the chemotherapy group. In the ATRA group, six patients relapsed after 7 to 15.5 months. In the chemotherapy group, 12 patients relapsed after 1 to 16 months, and 2 died in CR. Kaplan-Meier EFS was estimated at 79% +/- 7% and 50% +/- 9% at 12 months, respectively, in the ATRA and the chemotherapy group (P = .001). Kaplan-Meier estimate of relapse was 19% +/- 8% and 40% +/- 12% at 12 months (P = .005). In conclusion, ATRA followed by chemotherapy increases EFS in newly diagnosed APL. These results strongly suggest that ATRA should be incorporated in the front line therapy of newly diagnosed APL." @default.
• W79968274 created "2016-06-24" @default.
• W79968274 creator A5007750346 @default.
• W79968274 creator A5014838075 @default.
• W79968274 creator A5029887232 @default.
• W79968274 creator A5034349428 @default.
• W79968274 creator A5036003376 @default.
• W79968274 creator A5042465065 @default.
• W79968274 creator A5058825074 @default.
• W79968274 creator A5059745295 @default.
• W79968274 creator A5060464784 @default.
• W79968274 creator A5089177012 @default.
• W79968274 date "1993-12-01" @default.
• W79968274 modified "2023-10-11" @default.
• W79968274 title "Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group" @default.
• W79968274 cites W120786735 @default.
• W79968274 cites W1492718308 @default.
• W79968274 cites W1503457234 @default.
• W79968274 cites W1554600230 @default.
• W79968274 cites W1581043688 @default.
• W79968274 cites W183444608 @default.
• W79968274 cites W1963666059 @default.
• W79968274 cites W1965388358 @default.
• W79968274 cites W1979300931 @default.
• W79968274 cites W1981031972 @default.
• W79968274 cites W1990312495 @default.
• W79968274 cites W1991569222 @default.
• W79968274 cites W2037949275 @default.
• W79968274 cites W2039250506 @default.
• W79968274 cites W2046657068 @default.
• W79968274 cites W2053306416 @default.
• W79968274 cites W2058877087 @default.
• W79968274 cites W2063083122 @default.
• W79968274 cites W2076426515 @default.
• W79968274 cites W2077941517 @default.
• W79968274 cites W2127151679 @default.
• W79968274 cites W2157952933 @default.
• W79968274 cites W2187668060 @default.
• W79968274 cites W2252284689 @default.
• W79968274 cites W2256214571 @default.
• W79968274 cites W2269450671 @default.
• W79968274 cites W226946356 @default.
• W79968274 cites W2270961873 @default.
• W79968274 cites W2280629331 @default.
• W79968274 cites W2327237185 @default.
• W79968274 cites W2401587465 @default.
• W79968274 cites W2407345634 @default.
• W79968274 cites W2409883671 @default.
• W79968274 cites W2412330271 @default.
• W79968274 cites W2414768692 @default.
• W79968274 cites W2474307831 @default.
• W79968274 cites W2485184467 @default.
• W79968274 cites W2995133996 @default.
• W79968274 doi "https://doi.org/10.1182/blood.v82.11.3241.3241" @default.
• W79968274 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8241496" @default.
• W79968274 hasPublicationYear "1993" @default.
• W79968274 type Work @default.
• W79968274 sameAs 79968274 @default.
• W79968274 citedByCount "476" @default.
• W79968274 countsByYear W799682742012 @default.
• W79968274 countsByYear W799682742013 @default.
• W79968274 countsByYear W799682742014 @default.
• W79968274 countsByYear W799682742015 @default.
• W79968274 countsByYear W799682742016 @default.
• W79968274 countsByYear W799682742017 @default.
• W79968274 countsByYear W799682742018 @default.
• W79968274 countsByYear W799682742019 @default.
• W79968274 countsByYear W799682742020 @default.
• W79968274 countsByYear W799682742021 @default.
• W79968274 countsByYear W799682742022 @default.
• W79968274 countsByYear W799682742023 @default.
• W79968274 crossrefType "journal-article" @default.
• W79968274 hasAuthorship W79968274A5007750346 @default.
• W79968274 hasAuthorship W79968274A5014838075 @default.
• W79968274 hasAuthorship W79968274A5029887232 @default.
• W79968274 hasAuthorship W79968274A5034349428 @default.
• W79968274 hasAuthorship W79968274A5036003376 @default.
• W79968274 hasAuthorship W79968274A5042465065 @default.
• W79968274 hasAuthorship W79968274A5058825074 @default.
• W79968274 hasAuthorship W79968274A5059745295 @default.
• W79968274 hasAuthorship W79968274A5060464784 @default.
• W79968274 hasAuthorship W79968274A5089177012 @default.
• W79968274 hasBestOaLocation W799682741 @default.
• W79968274 hasConcept C104317684 @default.
• W79968274 hasConcept C126322002 @default.
• W79968274 hasConcept C141071460 @default.
• W79968274 hasConcept C168563851 @default.
• W79968274 hasConcept C203092338 @default.
• W79968274 hasConcept C2776601000 @default.
• W79968274 hasConcept C2776694085 @default.
• W79968274 hasConcept C2779936836 @default.
• W79968274 hasConcept C2781021840 @default.
• W79968274 hasConcept C2781121885 @default.
• W79968274 hasConcept C55493867 @default.
• W79968274 hasConcept C61943457 @default.
• W79968274 hasConcept C71924100 @default.
• W79968274 hasConcept C86803240 @default.
• W79968274 hasConcept C90924648 @default.

• next